Borislava G. Pavlova

1.3k total citations
43 papers, 1.0k citations indexed

About

Borislava G. Pavlova is a scholar working on Hematology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Borislava G. Pavlova has authored 43 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 10 papers in Infectious Diseases and 9 papers in Epidemiology. Recurrent topics in Borislava G. Pavlova's work include Platelet Disorders and Treatments (12 papers), Hemophilia Treatment and Research (10 papers) and Vector-borne infectious diseases (7 papers). Borislava G. Pavlova is often cited by papers focused on Platelet Disorders and Treatments (12 papers), Hemophilia Treatment and Research (10 papers) and Vector-borne infectious diseases (7 papers). Borislava G. Pavlova collaborates with scholars based in Austria, United States and Poland. Borislava G. Pavlova's co-authors include Sandor Fritsch, Hartmut J. Ehrlich, Perry Barrett, Alexandra Loew-Baselli, Alexandra Löw‐Baselli, Friedrich Maritsch, Otfried Kistner, Martin Bauer, Paul Anantharajah Tambyah and Markus Müller and has published in prestigious journals such as New England Journal of Medicine, Blood and The Journal of Infectious Diseases.

In The Last Decade

Borislava G. Pavlova

42 papers receiving 945 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Borislava G. Pavlova Austria 17 368 341 298 230 211 43 1.0k
Sandor Fritsch Austria 17 361 1.0× 425 1.2× 374 1.3× 172 0.7× 156 0.7× 30 1.1k
J. Hilfenhaus Germany 20 266 0.7× 385 1.1× 91 0.3× 96 0.4× 77 0.4× 71 965
Martin Spruth Austria 15 373 1.0× 180 0.5× 70 0.2× 164 0.7× 67 0.3× 22 765
Lee Major Australia 14 514 1.4× 161 0.5× 108 0.4× 541 2.4× 45 0.2× 17 984
J M Orenstein United States 15 278 0.8× 331 1.0× 53 0.2× 153 0.7× 240 1.1× 18 1.3k
G. Diego Miralles United States 16 532 1.4× 297 0.9× 69 0.2× 246 1.1× 62 0.3× 21 1.2k
Orlando C. Ferreira Brazil 19 360 1.0× 218 0.6× 71 0.2× 114 0.5× 32 0.2× 39 895
C M Black United States 18 146 0.4× 522 1.5× 106 0.4× 84 0.4× 47 0.2× 31 1.3k
Barry C. Cole United States 19 82 0.2× 390 1.1× 76 0.3× 98 0.4× 124 0.6× 41 1.2k
Alec E. Wittek United States 18 395 1.1× 997 2.9× 63 0.2× 44 0.2× 104 0.5× 30 1.4k

Countries citing papers authored by Borislava G. Pavlova

Since Specialization
Citations

This map shows the geographic impact of Borislava G. Pavlova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Borislava G. Pavlova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Borislava G. Pavlova more than expected).

Fields of papers citing papers by Borislava G. Pavlova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Borislava G. Pavlova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Borislava G. Pavlova. The network helps show where Borislava G. Pavlova may publish in the future.

Co-authorship network of co-authors of Borislava G. Pavlova

This figure shows the co-authorship network connecting the top 25 collaborators of Borislava G. Pavlova. A scholar is included among the top collaborators of Borislava G. Pavlova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Borislava G. Pavlova. Borislava G. Pavlova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maritsch, Friedrich, et al.. (2022). Data privacy protection in scientific publications: process implementation at a pharmaceutical company. BMC Medical Ethics. 23(1). 65–65. 7 indexed citations
2.
Hillson, Jan, Tim Mant, Donna Palmer, et al.. (2018). Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Pharmacology Research & Perspectives. 6(1). 14 indexed citations
3.
Manco‐Johnson, Marilyn J., Lisa Bomgaars, Amy D. Shapiro, et al.. (2016). Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thrombosis and Haemostasis. 116(7). 58–68. 23 indexed citations
4.
Brand, B., Ralph A. Gruppo, Tung Wynn, et al.. (2016). Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients. Haemophilia. 22(4). e251–8. 23 indexed citations
5.
Gill, Joan Cox, Giancarlo Castaman, Jerzy Windyga, et al.. (2015). Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 126(17). 2038–2046. 104 indexed citations
6.
7.
Prymula, Roman, Martin Bauer, Borislava G. Pavlova, et al.. (2012). Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior. Human Vaccines & Immunotherapeutics. 8(6). 736–742. 17 indexed citations
8.
Ehrlich, Hartmut J., Markus Müller, Herwig Kollaritsch, et al.. (2012). Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine. 30(30). 4543–4551. 14 indexed citations
9.
Saha, Sibu P., et al.. (2011). Use of Fibrin Sealant as a Hemostatic Agent in Expanded Polytetrafluoroethylene Graft Placement Surgery. Annals of Vascular Surgery. 25(6). 813–822. 21 indexed citations
10.
Tambyah, Paul Anantharajah, Annelies Wilder‐Smith, Borislava G. Pavlova, et al.. (2011). Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine. 30(2). 329–335. 22 indexed citations
11.
Bauer, Martin, Borislava G. Pavlova, Alexandra Löw‐Baselli, et al.. (2010). Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine. 28(29). 4680–4685. 25 indexed citations
12.
Ehrlich, Hartmut J., Markus Müller, Sandor Fritsch, et al.. (2009). A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses. The Journal of Infectious Diseases. 200(7). 1113–1118. 44 indexed citations
13.
Ehrlich, Hartmut J., Markus Müller, Helen May‐Lin Oh, et al.. (2008). A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture. New England Journal of Medicine. 358(24). 2573–2584. 204 indexed citations
14.
15.
Varga, Gyula, Heinz Leibl, Zoltán Gasztonyi, et al.. (2006). Efficacy and Safety of the New Intravenous Immunoglobulin IGIV 10% in Adults with Chronic Idiopathic Thrombocytopenic Purpura. Transfusion Medicine and Hemotherapy. 33(6). 509–514. 13 indexed citations
16.
Loew-Baselli, Alexandra, Ryszard Konior, Borislava G. Pavlova, et al.. (2006). Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN®: Results of two large phase 3 clinical studies. Vaccine. 24(24). 5256–5263. 51 indexed citations
17.
Kluger, Rainer, et al.. (2005). Osteoprogenitor Cells and Osteoblasts Are Targets for Hepatitis C Virus. Clinical Orthopaedics and Related Research. &NA;(433). 251–257. 2 indexed citations
18.
19.
Pavlova, Borislava G., et al.. (1999). Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential. Journal of Medical Virology. 57(4). 361–366. 18 indexed citations
20.
Pfeilstöcker, Michael, et al.. (1998). Monitoring of hematopoietic recovery after autologous stem cell transplantation by analysis of G alpha 16 mRNA and CD34 surface glycoprotein. Annals of Hematology. 76(3-4). 153–158. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandor Fritsch Breakdown of academic impact, for papers by J. Hilfenhaus Breakdown of academic impact, for papers by Martin Spruth Breakdown of academic impact, for papers by Lee Major Breakdown of academic impact, for papers by J M Orenstein Breakdown of academic impact, for papers by G. Diego Miralles Breakdown of academic impact, for papers by Orlando C. Ferreira Breakdown of academic impact, for papers by C M Black Breakdown of academic impact, for papers by Barry C. Cole Breakdown of academic impact, for papers by Alec E. Wittek
Rankless by CCL
2026